Boehringer Ingelheim GMBH became the first company to publicly disclose the start of a biosimilar interchangeability trial since the US FDA issued draft guidance on the subject, displaying a fair bit of confidence in a product the agency hasn't even approved yet.
BI said July 27 that the first patient has been enrolled in its VOLTAIRE-X trial, which is designed to determine...